Date: 2013-08-01
Type of information: Grant
Company: Prosensa (The Netherlands)
Investors: European Commission’s Seventh Framework Program (FP7)
Amount: €6 million
Funding type: grant
Planned used: The funds will be used to support the ongoing clinical study of the Company’s third novel development candidate, PRO045, for the treatment of Duchenne muscular dystrophy
Others: * On August 1, 2013, Prosensa, a Dutch biopharmaceutical company focusing on RNA-modulating therapeutics for rare diseases with high unmet need, has announced that it has been awarded a Framework Programme 7 (FP7) research grant from the European Union to support the ongoing clinical study of the Company’s third novel development candidate, PRO045 (exon 45-skipping drug candidate), for the treatment of Duchenne muscular dystrophy.
The project, titled \"Consortium for Products Across Europe in Duchenne Muscular Dystrophy” (SCOPE-DMD) is expected to run for three years. The consortium includes leading expert centers in DMD such as Newcastle University in the United Kingdom, the coordinating partner within the project, the Institute of Myology in France and Leiden University Medical Center in the Netherlands, as well as an industrial partner, BioSpring in Germany. The combined experience and expertise of this consortium will help advance the development of PRO045 which entered clinical trials earlier this year. PRO045 is currently in a Phase I/IIa dose-escalating safety study to assess its safety and efficacy. The compound induces exon 45 skipping in the dystrophin gene and could be suitable for approximately 8% of all DMD patients. PRO045 has been granted orphan drug status in the European Union and the United States.
Therapeutic area: Rare diseases - Neuromuscular diseases
